Quest Diagnostics®

Is it COVID-19, Flu, RSV, or something else?

Respiratory tests can help you make a precise diagnosis

This flu season, respiratory syncytial virus (RSV) rates are rising,[1] and we're still in the midst of the COVID-19 pandemic. SARS-CoV-2 (COVID-19), influenza A or B (flu), RSV, and other respiratory infections can present with similar symptoms such as fever, cough, and shortness of breath.

That's why it's important to consider testing for each of these contagious illnesses at the same time—especially for children, older adults, pregnant women, and people with underlying conditions or compromised immune systems.

Knowing which infection—or infections—are causing your patient's symptoms will help you make the best treatment decisions.

Whether caused by COVID-19, influenza, or another respiratory illness, the symptoms can be very similar[2]:

- Fever or feeling feverish/chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue (tiredness)
- Sore throat
- Runny or stuffy nose
- Muscle pain or body aches
- Headache
- Some people may have vomiting and diarrhea, though this is more common in children than adults

Cotesting options with Quest Diagnostics

Our testing options use a single specimen to cotest for common respiratory pathogens, which help expedite diagnosis so you can develop an appropriate treatment/care plan.

Visit QuestDiagnostics.com/Covid-19/HCP to learn more

Clinicians are encouraged to consider testing for other viral causes of respiratory illness, for example, influenza, in addition to testing for SARS-CoV-2.[3]

For more information, call your sales representative or
1.866.MY.QUEST (1.866.697.8378)

Identifying the source of infection is the first step in managing patient care

Quest offers the convenience of co-testing for influenza A and B and other respiratory pathogens in conjunction with testing for SARS-CoV-2.

Molecular Offerings and Panels for respiratory pathogen testing	Test code	CPT code(s)
NEW: SARS-CoV-2 RNA (COVID-19), Influenza A/B and RSV RNA, Qualitative NAAT	39816	0241U
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	39448	87635 (HCPCS:U0003)
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT	31688	87636
SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT	31686	87635 (HCPCS: U0003), 87633
SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT	31687	87635 (HCPCS: U0003), 87633, 87486, 87581

Molecular Respiratory Pathogen Tests and Panels (Non-COVID)	Test code	CPT code(s)
Influenza A and B RNA, Qualitative Real-Time PCR	16086	87502
Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR	16047	87634
Influenza A and B and RSV RNA, Qualitative, Real-Time RT-PCR	91989	87631
Respiratory Viral Panel, PCR	95512	87633
Respiratory Pathogen Panel	37444	87633, 87486 (*C. pneumoniae*), 87581 (*M. pneumoniae*)

Components of panels can be ordered separately. Components available individually include Adenovirus DNA, Qualitative, Real-Time PCR (Test Code 16046); Influenza A and B Virus with Subtyping, Real-Time PCR (Test Code 91335); Parainfluenza Virus (Types 1, 2, 3 and 4) RNA, Qualitative, Real-Time PCR (Test Code 91228), Rhinovirus RNA, Real-Time PCR (Test Code 40035); Enterovirus RNA, Qualitative, Real-Time PCR (Test Code 15082); Human Metapneumovirus RNA, Qualitative, Real-Time PCR (Test Code 40034); Chlamydophila pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 16003); Mycoplasma pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 15498).

Visit our test directory to learn more about our complete portfolio of respiratory infection tests

Count on Quest: the right test for the right patient for faster diagnosis and treatment

Leadership

A diagnostic leader during global health crises, Quest introduced a COVID-19 test 2 days before the virus was labeled a worldwide pandemic. We continue to deliver diagnostic insights to support the fight against COVID-19.

Convenience

Labs available nationwide to support increased testing volume in over 2,250 Patient Service Centers; integration with most EHRs through Quanum® Lab Services Manager.

History and expertise

Four decades of experience leading infectious disease testing during public health emergencies; experts available to help interpret test results.

Contact your Quest Diagnostics sales representative at
1.866.MY.QUEST (1.866.697.8378)

- The Cepheid SARS-CoV-2, Influenza A/B and RSV test, the cobas® SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests ("Tests") have not been FDA cleared or approved.
- The Roche® test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
- The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests.
- The Quest test and other molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

References:
1. CDC. RSV national trends. Updated August 25, 2021. Accessed August 26, 2021. https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html
2. CDC. Similarities and differences between flu and COVID-19. Updated June 7, 2021. Accessed September 1, 2021. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
3. CDC. Interim clinical guidance for patients with confirmed coronavirus disease (COVID-19). Updated February 16, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

Image content features models and is intended for illustrative purposes only.

Test codes may vary by location. Please contact your local laboratory for more information.

The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

QuestDiagnostics.com

Quest Diagnostics®